Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone

British Journal of Ophthalmology

Volumn 93, Issue 6, 2009, Pages 754-758

  Yip, P P ^a   Woo, C F ^b   Tang, H H Y ^a   Ho, C K ^a  

^a Tuen Mun Hosptial ^*  (Hong Kong)

^b Hong Kong Eye Associates   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INFARCTION; INTRAOCULAR PRESSURE; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; TREATMENT OUTCOME; TRIAMCINOLONE; VISUAL ACUITY; VITREOUS BODY;

EID: 66749143189     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.150987     Document Type: Article

References (25)

1. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642
2. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials: TAP report. Arch Ophthalmol 1999;117:1329-1345
3. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials: TAP report 2. Arch Ophthalmol 2001;119:198-207. (Pubitemid 32147926)
4. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment: TAP and VIP report No. 2. Arch Ophthalmol 2003;121:1253-1268
5. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in agerelated macular degeneration: two- year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2001;131:541-560 (Pubitemid 32427660)
6. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304 (Pubitemid 40202568)
7. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-645
8. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22. (Pubitemid 43021722)
9. Ruiz-Moreno JM, Montero JA, Barile S. Triamcinolone and PDT to treat exudative age-related macular degeneration and submacular hemorrhage. Eur J Ophthalmol 2006;16:426-434 (Pubitemid 44049286)
10. Jonas JB, Degenring R, Vossmerbauemer U, et al. Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide. Eur J Ophthalmol 2005;15:462-464 (Pubitemid 41152966)
11. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006;90:999-1003. (Pubitemid 44140181)
12. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2006;113:633-642
13. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature 2004;3:391-400. (Pubitemid 38618122)
14. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.e5. (Pubitemid 43296975)
15. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 2006;355:1419-1431 (Pubitemid 44511557)
16. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185 (Pubitemid 46829388)
17. FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration year 1 results of the FOCUS study. Arch Ophthalmol 2006;124:1532-1542 (Pubitemid 44748725)
18. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008;92:356-360
19. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-140 (Pubitemid 46245638)
20. Ahmadieh H, Taei R, Soheilian M, et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 2007;7:10. (Pubitemid 47025082)
21. Peyman GA, Kazi AA, Unal M, et al. Problems with and pitfalls of photodynamic therapy. Ophthalmology 2000;107:29-35. (Pubitemid 30210178)
22. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 1999;106:1915-1923
23. Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002;43:830-841 (Pubitemid 34184504)
24. Obata R, Inoue Yuji, Iriyama A, et al. Triamcinolone acetonide suppresses early proangiogenic response in RPE cells after photodynamic therapy in vitro. Br J Ophthalmol 2007;91:100-104 (Pubitemid 46094019)
25. Wang YS, Friedrichs U, Eichler W, et al. Inhibitory effects of triamcinolone acetonide on bFGF - induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002;240:42-48 (Pubitemid 36075572)